Connection

Carlo Perno to Humans

This is a "connection" page, showing publications Carlo Perno has written about Humans.
Connection Strength

0.118
  1. SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study. BMC Infect Dis. 2021 Feb 17; 21(1):184.
    View in: PubMed
    Score: 0.007
  2. Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy. PLoS One. 2020; 15(11):e0242765.
    View in: PubMed
    Score: 0.007
  3. Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients. PLoS One. 2020; 15(9):e0236311.
    View in: PubMed
    Score: 0.007
  4. Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients. J Infect. 2020 Sep; 81(3):e90-e92.
    View in: PubMed
    Score: 0.007
  5. Biotech innovations in the prevention of respiratory infectious diseases. New Microbiol. 2017 Jul; 40(3):155-160.
    View in: PubMed
    Score: 0.006
  6. Respiratory viruses and influenza-like illness: a survey in the area of Rome, winter 2004-2005. Euro Surveill. 2006; 11(10):251-3.
    View in: PubMed
    Score: 0.003
  7. Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects. Clin Chim Acta. 2021 Nov; 522:144-151.
    View in: PubMed
    Score: 0.002
  8. Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality. Clin Infect Dis. 2021 05 18; 72(10):1868-1869.
    View in: PubMed
    Score: 0.002
  9. Frontline Screening for SARS-CoV-2 Infection at Emergency Department Admission by Third Generation Rapid Antigen Test: Can We Spare RT-qPCR? Viruses. 2021 05 01; 13(5).
    View in: PubMed
    Score: 0.002
  10. School in Italy: a safe place for children and adolescents. Ital J Pediatr. 2021 Feb 02; 47(1):23.
    View in: PubMed
    Score: 0.002
  11. Mild Course of SARS-CoV-2 Infection in a Liver Transplant Recipient Undergoing Plasma Exchange and Defibrotide for Acute Graft Rejection. Transplantation. 2021 02 01; 105(2):e22-e24.
    View in: PubMed
    Score: 0.002
  12. Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy. Nat Commun. 2021 01 19; 12(1):434.
    View in: PubMed
    Score: 0.002
  13. Convalescent plasma for administration of passive antibodies against viral agents. Haematologica. 2020 12 01; 105(12):2710-2715.
    View in: PubMed
    Score: 0.002
  14. Development of machine learning models to predict RT-PCR results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with influenza-like symptoms using only basic clinical data. Scand J Trauma Resusc Emerg Med. 2020 Dec 01; 28(1):113.
    View in: PubMed
    Score: 0.002
  15. Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively. J Clin Microbiol. 2020 08 24; 58(9).
    View in: PubMed
    Score: 0.002
  16. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. J Infect. 2020 10; 81(4):e11-e17.
    View in: PubMed
    Score: 0.002
  17. Tuberculosis among asylum seekers in Milan, Italy: epidemiological analysis and evaluation of interventions. Eur Respir J. 2019 10; 54(4).
    View in: PubMed
    Score: 0.002
  18. Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. Virus Genes. 2019 Jun; 55(3):290-297.
    View in: PubMed
    Score: 0.002
  19. Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients. New Microbiol. 2019 Apr; 42(2):69-80.
    View in: PubMed
    Score: 0.002
  20. Real life experiences in HCV management in 2018. Expert Rev Anti Infect Ther. 2019 02; 17(2):117-128.
    View in: PubMed
    Score: 0.002
  21. Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. J Antimicrob Chemother. 2018 12 01; 73(12):3460-3470.
    View in: PubMed
    Score: 0.002
  22. New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). Chem Biol Drug Des. 2019 01; 93(1):50-59.
    View in: PubMed
    Score: 0.002
  23. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. Clin Microbiol Infect. 2019 Jul; 25(7):906.e1-906.e7.
    View in: PubMed
    Score: 0.002
  24. Viral resistance in HCV infection. Curr Opin Virol. 2018 10; 32:115-127.
    View in: PubMed
    Score: 0.002
  25. Different kinetics of viral replication and DNA integration in the main HIV-1 cellular reservoirs in the presence and absence of integrase inhibitors. Antiviral Res. 2018 12; 160:165-174.
    View in: PubMed
    Score: 0.002
  26. Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence. Sci Rep. 2018 10 24; 8(1):15739.
    View in: PubMed
    Score: 0.002
  27. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep. 2018 06 12; 8(1):8988.
    View in: PubMed
    Score: 0.002
  28. HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals. Infection. 2018 Oct; 46(5):717-720.
    View in: PubMed
    Score: 0.002
  29. The degree of HIV-1 amino acid variability is strictly related to different disease progression rates. Virus Genes. 2018 Aug; 54(4):493-501.
    View in: PubMed
    Score: 0.002
  30. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. BMC Infect Dis. 2018 05 16; 18(1):223.
    View in: PubMed
    Score: 0.002
  31. Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. J Clin Virol. 2018 07; 104:61-64.
    View in: PubMed
    Score: 0.002
  32. Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment. New Microbiol. 2018 Apr; 41(2):112-117.
    View in: PubMed
    Score: 0.002
  33. High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance. PLoS One. 2018; 13(3):e0195045.
    View in: PubMed
    Score: 0.002
  34. Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Biol Blood Marrow Transplant. 2018 08; 24(8):1699-1706.
    View in: PubMed
    Score: 0.002
  35. Cytomegalovirus Glycoprotein B Genotype Distribution in Italian Transplant Patients. Intervirology. 2017; 60(4):165-170.
    View in: PubMed
    Score: 0.002
  36. Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. Antivir Ther. 2018; 23(3):249-257.
    View in: PubMed
    Score: 0.001
  37. Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study. J Antimicrob Chemother. 2017 Dec 01; 72(12):3420-3424.
    View in: PubMed
    Score: 0.001
  38. Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy. Clin Gastroenterol Hepatol. 2018 06; 16(6):977-978.
    View in: PubMed
    Score: 0.001
  39. Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14. J Antimicrob Chemother. 2017 10 01; 72(10):2837-2845.
    View in: PubMed
    Score: 0.001
  40. Effects of Amprenavir on HIV-1 Maturation, Production and Infectivity Following Drug Withdrawal in Chronically-Infected Monocytes/Macrophages. Viruses. 2017 09 28; 9(10).
    View in: PubMed
    Score: 0.001
  41. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? J Hepatol. 2018 03; 68(3):597-600.
    View in: PubMed
    Score: 0.001
  42. Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. J Clin Microbiol. 2017 09; 55(9):2827-2837.
    View in: PubMed
    Score: 0.001
  43. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infect. 2017 Dec; 23(12):935-940.
    View in: PubMed
    Score: 0.001
  44. Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients? Ann Hematol. 2017 Aug; 96(8):1253-1270.
    View in: PubMed
    Score: 0.001
  45. Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS One. 2017; 12(5):e0177352.
    View in: PubMed
    Score: 0.001
  46. Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation. Dig Dis Sci. 2017 Aug; 62(8):2193-2195.
    View in: PubMed
    Score: 0.001
  47. Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation. J Antimicrob Chemother. 2017 05 01; 72(5):1537-1539.
    View in: PubMed
    Score: 0.001
  48. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life. Clin Microbiol Infect. 2017 Oct; 23(10):777.e1-777.e4.
    View in: PubMed
    Score: 0.001
  49. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. Dig Liver Dis. 2017 Jul; 49(7):731-741.
    View in: PubMed
    Score: 0.001
  50. HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay. J Virol Methods. 2017 08; 246:1-7.
    View in: PubMed
    Score: 0.001
  51. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 06; 2(6):427-434.
    View in: PubMed
    Score: 0.001
  52. Clinical features and outcome of hospitalized patients with HSV-1 DNA in the lower respiratory tract. New Microbiol. 2017 Apr; 40(2):107-112.
    View in: PubMed
    Score: 0.001
  53. Occupational HIV Infection in a Research Laboratory With Unknown Mode of Transmission: A Case Report. Clin Infect Dis. 2017 03 15; 64(6):810-813.
    View in: PubMed
    Score: 0.001
  54. Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy. BMC Evol Biol. 2017 03 07; 17(1):70.
    View in: PubMed
    Score: 0.001
  55. Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro. Oncotarget. 2017 Feb 28; 8(9):15704-15715.
    View in: PubMed
    Score: 0.001
  56. Thymosin alpha 1 and HIV-1: recent advances and future perspectives. Future Microbiol. 2017 02; 12:141-155.
    View in: PubMed
    Score: 0.001
  57. Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child. BMC Infect Dis. 2016 Dec 09; 16(1):742.
    View in: PubMed
    Score: 0.001
  58. Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain. J Drug Target. 2009 May; 17(4):278-85.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.